Article ; Online: LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?
Current atherosclerosis reports
2022 Volume 24, Issue 8, Page(s) 635–642
Abstract: Purpose of review: Low-density lipoprotein cholesterol (LDL-C) is the most important causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This article reviews why LDL-C remains overlooked and underestimated despite numerous studies ... ...
Abstract | Purpose of review: Low-density lipoprotein cholesterol (LDL-C) is the most important causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This article reviews why LDL-C remains overlooked and underestimated despite numerous studies that have proved its role. Recent findings: Recently published EAS/ESC Guidelines for dyslipidemia and EAS Guidelines for prevention set new targets for LDL-C levels in primary and secondary prevention of ASCVD. These guidelines are based on data from large studies and meta-analyzes that have shown that lower LDL-C also means lower cardiovascular event rates. Real-life experience published in registries worldwide has shown us that the guidelines have not been translated to everyday clinical practice, meaning that a significant number of patients are undertreated and have LDL-C levels well above target. Potential reasons for the abovementioned are poor adherence and education of the patient and physician and health care system related factors. Implementation of the latest version of guidelines will require continuous patient and physicians education, as well as a shared decision-making process between physician and patient. |
---|---|
MeSH term(s) | Atherosclerosis/drug therapy ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Cholesterol, LDL ; Dyslipidemias/drug therapy ; Dyslipidemias/epidemiology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Risk Factors |
Chemical Substances | Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Language | English |
Publishing date | 2022-05-28 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 2057369-8 |
ISSN | 1534-6242 ; 1523-3804 |
ISSN (online) | 1534-6242 |
ISSN | 1523-3804 |
DOI | 10.1007/s11883-022-01037-3 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5534: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.